Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

BIOLOGICAL(4)
MIXED(2)
DRUG(1)
CART-19
3 trials
phase_1phase_2
university-of-pennsylvania
CTL019
1 trial
phase_2
abramson-cancer-center-at-penn-medicine
Birinapant
1 trial
phase_1_2
abramson-cancer-center-at-penn-medicine
Eltrombopag
1 trial
phase_1_2
abramson-cancer-center-at-penn-medicine
CART22 cells
1 trial
phase_1
university-of-pennsylvania
5 unique interventions3 categories

Analytics

Trial Phases

Phase 14
Phase 25

Trial Status

Completed3
Terminated3
Other1

Role Distribution

Principal Investigator7
PI Rate100%

Activity Timeline

Clinical Trials (7)

NCT02030847Phase 2Completed
Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
PrincipalinvestigatorStart date: 2014-02-27
NCT01747486Phase 2Completed
Dose Optimization Trial of CD19 Redirected Autologous T Cells
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
PrincipalinvestigatorStart date: 2013-01-02
NCT01113502Phase 1/2Terminated
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
Acute Myelogenous Leukemia (AML)
PrincipalinvestigatorStart date: 2010-06-01
NCT01029366Phase 1Completed
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
Adult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic Leukemia+20 more
PrincipalinvestigatorStart date: 2010-03-17
NCT01486784Phase 1/2Terminated
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Principalinvestigator
NCT02167360Phase 2Withdrawn
Study of Efficacy and Safety of CTL019 in Adult ALL Patients
B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic LeukemiaRelapsed B-cell Acute Lymphoblastic Leukemia
Principalinvestigator
NCT02588456Phase 1Terminated
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellRecurrent Grade 1 Follicular Lymphoma+2 more
Similarity Score5%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteB-cell Acute Lymphoblastic Leukemia
Similarity Score3%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Recurrent Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell Lymphoma
Similarity Score3%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellRelapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Similarity Score2%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score2%

Yves Beguin, MD, PhD

CHU-ULg

Related
7 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, Acute
Similarity Score2%

David Avigan, MD

Beth Israel Deaconess Medical Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score2%

Beata Holkova, MD

Massey Cancer Center

Related
3 trials

Shared therapeutic areas:

Leukemia, Myeloid, Acute
Similarity Score1%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Leukemia, Myeloid, Acute
Similarity Score1%

emilie garrido pradalie

APHM

Related
35 trials

Shared therapeutic areas:

Hematopoietic/Lymphoid Cancer
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (7)

Showing 7 of 7 trials

NCT02030847Phase 2PrincipalInvestigator

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Completed
NCT01747486Phase 2PrincipalInvestigator

Dose Optimization Trial of CD19 Redirected Autologous T Cells

Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
Completed
NCT01113502Phase 1/2PrincipalInvestigator

Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia (AML)
Terminated
NCT01029366Phase 1PrincipalInvestigator

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Adult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic Leukemia+20 more
Completed
NCT01486784Phase 1/2PrincipalInvestigator

A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia

Acute Myelogenous Leukemia
Terminated
NCT02167360Phase 2PrincipalInvestigator

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic LeukemiaRelapsed B-cell Acute Lymphoblastic Leukemia
Withdrawn
NCT02588456Phase 1PrincipalInvestigator

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Terminated

All 7 trials loaded